文献速递乳腺US

对比增强超声对超声BI-RADS 4类乳腺病灶活检决策附加价值的前瞻性多中心研究

A Prospective Multicenter Study on the Additive Value of Contrast-Enhanced Ultrasound for Biopsy Decision of Ultrasound BI-RADS 4 Breast Lesions.
PubMed 文献 · Ultrasound Med Biol · 2024-05-24

这项前瞻性多中心研究纳入中国8家教学医院2017年1月至2018年12月经常规超声诊断为BI-RADS 4类的1490个实性乳腺病灶,在诊断后1周内行对比增强超声(CEUS)重新分类,以组织病理为参考标准。CEUS重分类后882个(59%)仍为BI-RADS 4类,以CEUS-BI-RADS 4A为活检切点时活检率降至73.4%、癌活检检出率由32.6%升至43.4%,仅2.5%(12/486)恶性病灶被误分为BI-RADS 3类。结论认为CEUS有助于BI-RADS 4类病灶进一步分诊、减少活检数量并提高癌活检检出率。

要点

  • CEUS重分类后仅2.5%(12/486)恶性病灶被误分为BI-RADS 3类。
  • 以CEUS-BI-RADS 4A为活检切点时癌活检检出率由32.6%升至43.4%。
  • CEUS重分类的诊断准确率57.65%、敏感度97.53%、特异度38.35%。

核心结论

  • CEUS有助于进一步分诊BI-RADS 4类病灶,减少活检数量并提高癌活检检出率。

研究设计与样本

  • 前瞻性多中心研究,2017年1月至2018年12月纳入中国8家教学医院经常规超声诊断为BI-RADS 4类的实性乳腺病灶共1490个,诊断后1周内行CEUS重新分类,以空心针活检或手术切除标本的组织病理结果为参考标准。

诊断标准与关键数值

  • 以CEUS-BI-RADS 4A为活检切点时,模拟活检率降至73.4%,癌活检检出率由基于常规超声的32.6%升至43.4%。

临床应用与阅片要点

  • 作者认为CEUS是BI-RADS 4类病灶进一步分诊的有价值工具,可减少活检数量并提高癌活检检出率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The main aim of this study was to determine whether the use of contrast-enhanced ultrasound (CEUS) could improve the categorization of suspicious breast lesions based on the Breast Imaging Reporting and Data System (BI-RADS), thereby reducing the number of benign breast lesions referred for biopsy.

METHODS: This prospective study, conducted between January 2017 and December 2018, enrolled consenting patients from eight teaching hospitals in China, who had been diagnosed with solid breast lesions classified as BI-RADS 4 using conventional ultrasound. CEUS was performed within 1 wk of diagnosis for reclassification of breast lesions. Histopathological results obtained from core needle biopsies or surgical excision samples served as the reference standard. The simulated biopsy rate and cancer-to-biopsy yield were used to compare the accuracy of CEUS and conventional ultrasound (US).

RESULTS: Among the 1490 lesions diagnosed as BI-RADS 4 with conventional ultrasound, 486 malignant and 1004 benign lesions were confirmed based on histology. Following CEUS, 2, 395, and 211 lesions were reclassified as CEUS-based BI-RADS 2, 3, and 5, respectively, while 882 (59%) remained as BI-RADS 4. The actual cancer-to-biopsy yield based on US was 32.6%, which increased to 43.4% when CEUS-based BI-RADS 4A was used as the cut-off point to recommend biopsy. The simulated biopsy rate decreased to 73.4%. Overall, in this preselected BI-RADS 4 population, only 2.5% (12/486) of malignant lesions would have been miscategorized as BI-RADS 3 using CEUS-based reclassification. The diagnostic accuracy, sensitivity, and specificity of contrast-enhanced ultrasound reclassification were 57.65%, 97.53%, and 38.35%, respectively.

CONCLUSION: Our collective findings indicate that CEUS is a valuable tool in further triage of BI-RADS category 4 lesions and facilitates a reduction in the number of biopsies while increasing the cancer-to-biopsy yield.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Luo J, Tang L, Chen Y, et al. A Prospective Multicenter Study on the Additive Value of Contrast-Enhanced Ultrasound for Biopsy Decision of Ultrasound BI-RADS 4 Breast Lesions. Ultrasound Med Biol. 2024. PMID: 38796340. doi:10.1016/j.ultrasmedbio.2024.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。